Genmab Completes Accrual in HuMax-CD20(TM) Phase I/II CLL Study

01-Apr-2005

Genmab A/S announced that it has completed enrolment in the HuMax-CD20 Phase I/II study to treat patients with chronic lymphocytic leukemia (CLL). A total of 33 patients are enrolled in this study, with 27 patients included in the highest dose group, where they receive an initial dose of 500 mg followed by three weekly doses of 2000 mg.

"The team at Genmab has worked hard to ensure rapid recruitment in this study," said Lisa N. Drakeman, Ph.D., Chief Executive Officer of Genmab. "We look forward to seeing efficacy data from this study."

The first important milestone for this study, the safety of using HuMax-CD20 in these patients at the planned dose levels, seems to have been achieved since no side effects limiting the continued recruitment of patients were observed.

The total follow up period for this study is 12 months from treatment start and the primary endpoint of the trial is objective response over the period from screening to week 19.

Other news from the department research and development

Most read news

More news from our other portals

Fighting cancer: latest developments and advances